Effective Surface Sterilisation/Decontamination of Freeze Drying Equipment
SP Scientific has partnered with Bioquell to produce an off-the-shelf surface sterilisation/decontamination system for SP freeze dryers.
The freeze drying production of many pharmaceuticals and biological materials requires sterile conditions. Traditionally, freeze dryers have used steam for sterilization. Unfortunately working with steam means that the freeze dryers are exposed to many different stresses and strains. SP Scientific, in conjunction with Bioquell, have developed an equally effective and less expensive solution to perform surface sterilization/decontamination of freeze dryers using hydrogen peroxide vapor (HPV).
HPV is well established as a biodecontamination agent due to its broad spectrum efficacy and its ability to inactivate rapidly the most resilient micro-organisms. The residue-free nature of HPV (breaks down to oxygen and water vapor) and low temperature, vapor-phase application increases the practicality of the process. Bioquell’s HPV technology has been tested and proven effective against many organisms including bacteria, bacterial endospores, viruses, bacteriophage, fungi, nematodes and protozoa.
Surface sterilisation/decontamination using the HPV system is remarkably quick enabling fast turnaround of your freeze dryer for further work. Typically lab-scale freeze dryers can be sterilized in just 1–2 hours, pilot-scale freeze dryers in 2–3 hours and production-scale freeze dryers in less than 4 hours. The HPV system is easy-to-use and simply integrated with your SP Scientific freeze dryer without need for excessive external piping or critical utilities that are commonly required to support steam sterilisers.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.